key: cord-0777522-4pp1dr4f
authors: Meyts, Isabelle; Bucciol, Giorgia; Quinti, Isabella; Neven, Bénédicte; Fischer, Alain; Seoane, Elena; Lopez-Granados, Eduardo; Gianelli, Carla; Robles-Marhuenda, Angel; Jeandel, Pierre-Yves; Paillard, Catherine; Sankaran, Vijay G.; Demirdag, Yesim Yilmaz; Lougaris, Vassilios; Aiuti, Alessandro; Plebani, Alessandro; Milito, Cinzia; Dalm, Virgil ASH.; Guevara-Hoyer, Kissy; Sánchez-Ramón, Silvia; Bezrodnik, Liliana; Barzaghi, Federica; Gonzalez-Granado, Luis Ignacio; Hayman, Grant R.; Uzel, Gulbu; Mendonça, Leonardo Oliveira; Agostini, Carlo; Spadaro, Giuseppe; Badolato, Raffaele; Soresina, Annarosa; Vermeulen, François; Bosteels, Cedric; Lambrecht, Bart N.; Keller, Michael; Mustillo, Peter J.; Abraham, Roshini S.; Gupta, Sudhir; Ozen, Ahmet; Karakoc-Aydiner, Elif; Baris, Safa; Freeman, Alexandra F.; Yamazaki-Nakashimada, Marco; Scheffler-Mendoza, Selma; Espinosa-Padilla, Sara; Gennery, Andrew R.; Jolles, Stephen; Espinosa, Yazmin; Poli, M. Cecilia; Fieschi, Claire; Hauck, Fabian; Cunningham-Rundles, Charlotte; Mahlaoui, Nizar; Warnatz, Klaus; Sullivan, Kathleen E.; Tangye, Stuart G.
title: Coronavirus disease 2019 in patients with inborn errors of immunity: An international study
date: 2020-09-24
journal: J Allergy Clin Immunol
DOI: 10.1016/j.jaci.2020.09.010
sha: 4530907406b61e826271940b714d186484a1773f
doc_id: 777522
cord_uid: 4pp1dr4f

BACKGROUND: There is uncertainty about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in individuals with rare inborn errors of immunity (IEI), a population at risk of developing severe coronavirus disease 2019. This is relevant not only for these patients but also for the general population, because studies of IEIs can unveil key requirements for host defense. OBJECTIVE: We sought to describe the presentation, manifestations, and outcome of SARS-CoV-2 infection in IEI to inform physicians and enhance understanding of host defense against SARS-CoV-2. METHODS: An invitation to participate in a retrospective study was distributed globally to scientific, medical, and patient societies involved in the care and advocacy for patients with IEI. RESULTS: We gathered information on 94 patients with IEI with SARS-CoV-2 infection. Their median age was 25 to 34 years. Fifty-three patients (56%) suffered from primary antibody deficiency, 9 (9.6%) had immune dysregulation syndrome, 6 (6.4%) a phagocyte defect, 7 (7.4%) an autoinflammatory disorder, 14 (15%) a combined immunodeficiency, 3 (3%) an innate immune defect, and 2 (2%) bone marrow failure. Ten were asymptomatic, 25 were treated as outpatients, 28 required admission without intensive care or ventilation, 13 required noninvasive ventilation or oxygen administration, 18 were admitted to intensive care units, 12 required invasive ventilation, and 3 required extracorporeal membrane oxygenation. Nine patients (7 adults and 2 children) died. CONCLUSIONS: This study demonstrates that (1) more than 30% of patients with IEI had mild coronavirus disease 2019 (COVID-19) and (2) risk factors predisposing to severe disease/mortality in the general population also seemed to affect patients with IEI, including more younger patients. Further studies will identify pathways that are associated with increased risk of severe disease and are nonredundant or redundant for protection against SARS-CoV-2.

Conclusions: This study demonstrates that (1) more than 30% of patients with IEI had mild coronavirus disease 2019 (COVID- 19) and (2) risk factors predisposing to severe disease/mortality in the general population also seemed to affect patients with IEI, including more younger patients. Further studies will identify pathways that are associated with increased risk of severe disease and are nonredundant or redundant for protection against SARS-CoV-2. (J Allergy Clin Immunol 2020;nnn:nnnnnn.)

Key words: SARS-CoV-2, COVID-19, primary immunodeficiencies, inborn errors of immunity, hypogammaglobulinemia, immune dysregulation In December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a single-stranded RNA virus, emerged in the Hubei province of China as a novel human pathogen. SARS-CoV-2 causes an infectious disease (coronavirus disease 2019 ) characterized by pneumonia and acute respiratory failure. 1-4 SARS-CoV-2 infects human cells by binding to the angiotensin-converting enzyme 2, which is expressed predominantly by lung and intestinal epithelial cells, alveolar cells, and vascular endothelial cells. SARS-CoV-2 spreads within the human population mainly via droplet transmission and has infected more than 40 million individuals, causing more than 1.1 million deaths. There is a broad clinical spectrum including asymptomatic infection, mild infection (fever, fatigue, diarrhea, vomiting, myalgia, dry cough, dyspnea, and pneumonia), respiratory failure, myocarditis, thromboembolism, and finally fatal multiorgan failure. 5, 6 The pathophysiology of COVID-19 results from direct cytopathic effects of SARS-CoV-2 on respiratory epithelia, endothelia, and other organ-specific cell types, and subsequent induction of a proinflammatory cytokine storm and dysregulated adaptive immunity causing severe tissue damage. 7 Current epidemiology studies indicate that the case-fatality rate of SARS-CoV-2 infection ranges from 1% to 20%, while the infection fatality rate is 0.2% to 1.3%. 8, 9 Despite this variability, the lethality of SARS-CoV-2 infection consistently and dramatically increases with each decade of life beyond age 50 years 10 (Table I) . Furthermore, pre-existing comorbidities (chronic lung/heart disease, obesity, diabetes, hypertension) have been reported to contribute to a more severe course of COVID-19. 11, 12 Importantly, the occurrence of a multisystemic hyperinflammatory syndrome in children (MIS-C) has challenged the perception that SARS-CoV-2 infection is mild in young individuals. 13, 14 In most countries, more males than females have presented with symptomatic SARS-CoV-2 infection, indicating that sex can influence disease course and/or outcome. 10 Another contributor to interindividual susceptibility to severe COVID-19 and outcome postinfection is genetic heterogeneity. 15 This reflects the discoveries of patients with inborn errors of immunity (IEI) who exhibit increased susceptibility to pathogen infection. 16, 17 Although more than 430 monogenic IEIs have been described, [16] [17] [18] the consequences of SARS-CoV-2 infection have been reported for only a few individuals with these conditions. [19] [20] [21] [22] Thus, the aim of this multicenter, retrospective international study was to assess the impact of SARS-CoV-2 infection on patients with IEIs, thereby providing the first comprehensive description on the susceptibility of an at-risk population of patients to SARS-CoV-2 infection, as well as their COVID-19 clinical course, severity, complications, and outcomes. This extensive global data set represents an important reference for clinicians treating and managing patients with IEIs in the context of the COVID-19 pandemic.

A retrospective study was undertaken by a web-based survey, approved by the University Hospitals Leuven Committee for Medical Ethics. The questionnaire inquired about demographic data, COVID-19 presentation, treatment, and outcomes in patients with IEIs (according to current diagnostic guidelines) and documented SARS-CoV-2 infection. No identifying information was required, while physicians were given the option of providing their contact details. The survey opened on March 16, 2020, and closed on June 30, 2020. An invitation to participate in the survey was shared with members of various societies (European Society for Immunodeficiencies, Clinical Immunology Society, Latin American Society for Immunodeficiencies, African Society for Immunodeficiencies, Asia Pacific Society for Immunodeficiencies, Australasian Society for Clinical Immunology & Allergy), as well as via the International Patient Organization for Primary Immunodeficiencies, the Jeffrey Modell Foundation, and the International Union of Immunological Societies Committee for Inborn Errors of Immunity, with the aid of social media alerts. Fisher exact test of independence and Bayesian analysis of contingency tables were used to calculate the statistical significance of the correlation between categorical variables.

A total of 94 patients with an underlying primary immunodeficiency (PID)/IEI and infected by SARS-CoV-2, as determined by serology (n 5 8) or diagnostic PCR (n 5 86), were reported (Tables I and II ). Male to female ratio was 1.8 to 1. Thirty-two patients were younger than 18 years and 62 were adults (median age group, 25-34 years). Eleven patients have been reported previously. [19] [20] [21] 23 Types and causes of IEI Table II ).

There were also 29 patients with common variable immune deficiency (CVID) and 2 patients with syndromic features (P1: cardiomyopathy and neutropenia; P41: ventricular septum defect and CD4 1 T-cell lymphopenia; Table II) . Forty-six of 53 antibody-deficient patients received immunoglobulin substitution as standard therapy and 6 received immunosuppressive therapy.

Six patients had phagocyte defects: 4 with X-linked (variants in CYBB [P8, P88, and P92]) or recessive (bialleic variants in NCF2 [P89]) chronic granulomatous disease (CGD); 1 (P88) was treated with cyclosporin (Fig 1 and Table II (Table II) . Seven additional patients suffered from an autoinflammatory disease (Fig 1 and Table II) One patient suffered from bone marrow failure caused by biallelic DNAJC21 mutations (P36), and 1 had pancytopenia due to a heterozygous GATA2 variant (P94) (Fig 1 and Table II) .

Before infection, all patients were stable on standard of care treatment; 2 were on angiotensin-converting enzyme inhibitor therapy. The most frequent presenting symptoms were fever (69%) and cough (47%), followed by upper respiratory tract symptoms (runny nose, sneezing: 19%) and shortness of breath/ dyspnea (13%). Gastrointestinal symptoms (diarrhea, vomiting) and myalgia were reported in 14% and 16% of patients, respectively, while acute respiratory insufficiency was the presenting feature in 11% of patients. Other reported symptoms were fatigue, sore throat, anosmia/ageusia, collapse, pallor, and anemia. (Table II) . In these cases, testing for SARS-CoV-2 was performed only to enable travel, elective treatment, or due to positivity of a symptomatic relative/close contact.

Twenty-four patients had mild disease and were treated as outpatients (Table II) . Two were 3-12 years old, 1 was 19-24 years, 6 were 25-34 years, 5 were 35-44 years, 3 were 45-54 years, 2 were 55-64 years, 4 were 65-74 years, and 1 was older than 75 years. These patients included d 14 with predominantly antibody deficiency (11 with CVID, of whom 7 had > _1comorbidity); d 1 patient with X-SCID with persistent defective B-cell function after gene therapy; d 1 with activated PI3 kinase syndrome (P51, PIK3R1 mutation); d 1 with CID with multiple autoimmune features (P75); d 3 with hyper-IgE syndrome due to PGM3 deficiency (P76), or STAT3 loss-of function (P77 and P78) including 1 with chronic lung disease; and d 2 with MEFV mutations (P79 and P80), 1 with AGS (P83, SAMHD1 mutation), 1 with CGD due to CYBB mutation (P92), and 1 with an unspecified phagocyte defect (P90).

Fifty-nine patients (63%) required hospitalization. Clinical progression of 29 of these 59 patients evolved into respiratory insufficiency (49% of hospitalized, 31% of all patients). Thirteen patients required noninvasive ventilation/oxygen administration, and 15 ( succumbed, see below). In addition, individual patients were admitted to ICU for severe AIHA (P36), hypotension (P94), or MIS-C and miliary Mycobacterium avium infection (P38; IFNGR2) but no respiratory complications. Among female patients admitted to ICU for respiratory insufficiency, 2 had CVID and were aged 55-64 years (P3 and P4), 1 was older than 75 years (hypogammaglobulinemia; P5), and one was younger than 2 years with trisomy 21 and chronic invasive ventilation via tracheostomy in the context of congenital heart disease (P17). In contrast, the age distribution of the 11 affected males admitted to ICU was broader than for females, and the general population (Tables I and II) : The three patients with trisomy 21 experienced acute respiratory insufficiency, requiring invasive (P15 and P17) or noninvasive (P26) ventilation. P15 and P17 also had a pre-existing heart condition; P17 required a tracheostomy and chronic ventilation. Overall, 73% (11 of 15) of the patients needing invasive ventilation had pre-existing comorbidities (Fig 1 and Table II) .

Reported complications, as defined according to international guidelines 26, 27 or current practice, 13, 14 were bacterial pneumonia (n 5 6), hemophagocytic lymphohistiocytosis (HLH) (n 5 6), sepsis (n 5 6 [7%]), MIS-C (P38, IFNGR2, 1%), and kidney failure (n 5 5 [5%]). Two patients had sepsis and HLH. Furthermore, individual patients developed AIHA, thrombocytopenia, hyporegenerative anemia, neutropenia, myocarditis, and heart failure.

Nine patients in this cohort (7 adults and 2 children, 10%) died (Fig 1 and Table II) , Table II ) had X-CGD, concomitant Burkholderia sepsis, and HLH. The other child (P9, 13-18 years) had severe gut graft versus host disease following HSCT for XIAP deficiency and developed septic shock and HLH. Thus, it is unclear how much SARS-CoV-2 infection contributed to the death in both children. P1 (male, 35-44 years) suffered a syndromic disease with congenital dysmorphisms, mild developmental delay, hypogammaglobulinemia, neutropenia, hypertrophic cardiomyopathy, and bronchopathy. He developed pneumothorax, pulmonary hypertension, and heart failure after SARS-CoV-2 infection and died despite treatment with antibiotics, immunoglobulin infusion, steroids, and extracorporeal membrane oxygenation. The other deceased patients (5 females and 1 male) suffered from antibody deficiencies (CVID [P2, P3, P4, and P7]; isolated IgG deficiency [P5]; IgA and IgG 2 deficiency [P6]; Table II ). Most patients were treated for potential bacterial coinfection or superinfection with antibiotics and extra immunoglobulin infusion.

All adult patients with PID who succumbed to SARS-CoV-2 infection had pre-existing comorbidities (Fig 1 and Table II) : P1 had cardiomyopathy and developed pulmonary hypertension and heart failure; P2 had chronic kidney disease, underwent kidney transplant, and had several malignancies; all other patients were older than 55 years, and P3 had chronic lung and heart disease; P4 had chronic lung disease and developed sepsis; P5 had chronic lung, heart, and kidney disease, hypertension, and diabetes; P6 had diabetes; P7 had lymphoproliferative disease, gastrointestinal disease, and genital tract neoplasm and developed Enterococcus faecium sepsis. P2, P3, P5, P6, and P7 all developed hypotension and kidney failure during COVID-19. However, exact cause of COVID-19-related deaths for these patients is unknown.

Therapeutic strategies varied greatly and consisted of the following medications, alone or in combination: antibiotics The association between outcome (alive/dead) and the onset of respiratory insufficiency, the presence of comorbidities, or the sex of the patient was not significantly different between patients who survived or patients who succumbed to SARS-CoV-2. Moreover, no correlation could be found between outcome and respiratory insufficiency, age groups, or PID type. Individual patient categories were too small to allow for multivariate analysis.

Individuals with IEIs, and subsequent immune deficiency or immune dysregulation, are a priori considered an at-risk population for developing severe COVID-19 following SARS-CoV2 infection. Although a few studies have reported outcomes of SARS-CoV-2 infection in small numbers of patients with PID, [19] [20] [21] [22] the impact of the COVID-19 pandemic on the broader global population of these patients has not been established. Here, we report the occurrence and course of SARS-CoV-2 infection in 94 patients with IEI. Distribution between diagnostic IEI categories reflected that of large patient registries (esidregistry. org; usidnet.org). Thus, patients with antibody deficiencies are the predominant group with COVID, and approximately 20% of patients had CIDs or impaired innate immunity (Fig 1) .

Overall, presentation and risk factors (eg, pre-existing heart, lung, or kidney disease) for severe COVID-19 in patients with IEI seem very similar to those in the general population. Case-fatality rate was approximately 10%, in line with global data from the general population (1%-20%, Table I ). 1, 10, 28, 29 The mortality rate may actually be lower, because death of some patients may have resulted from IEI, rather than SARS-CoV-2 infection (eg, Burkholderia infection in P8 [X-CGD]; severe graft versus host disease in P9 [XIAP deficiency, post-HSCT]). Thus, perhaps surprisingly, the inherent immunocompromised state of the patients studied here was generally not a predominant risk factor for severe COVID-19. Similar to some epidemiological analyses, 28 there was a male predominance among all patients with IEI (1.8:1), as well as those admitted to ICU (2.8:1). The sex ratio among patients with CVID with a more severe course (requiring at least oxygen) was also strongly skewed toward males (M:F, 8:5) . However, there are apparent differences in the age distribution of patients with IEI affected by SARS-CoV-2 (median age, 25-34 years) as well as the frequency of ICU admissions (16%) compared with the general population (Table I) . 10 Our study suggests that younger male patients with IEI are more likely to endure severe COVID-19 and require ICU admission. This skewing is not explained by the inclusion of X-linked disorders in this cohort (n 5 13). Rather, differential levels of inflammatory mediators, T-cell responses, and/or virus-specific antibodies between infected males and females may explain the predominance of males with severe COVID-19. 30 One of the key findings from our study is the identification of both redundancies in the human immune system for host defense against SARS-CoV-2 and putative mediators of immune pathology following viral infection. First, many patients with defects predominantly in the adaptive immune system (eg, defective humoral [XLA, agammaglobulinemia, persisting humoral immunodeficiency in X-SCID after gene therapy] and/or T-cell [ZAP70, PGM3, STAT3, ARPC1B mutations] responses) were either asymptomatic or had only mild disease and promptly recovered (Table II; see references [19] [20] [21] [22] . Similarly, 11 patients with CVID had mild disease and did not require hospital admission, despite several having comorbidities. Thus, certain components of adaptive immunity do not appear to be essential for controlling SARS-CoV-2 infection. Rather, these adaptive immune deficiencies may even contribute to a milder course by reducing the immune-mediated sequelae. This is consistent with findings that patients with IEIs that specifically affect B-and T-cell development or function do not exhibit increased susceptibility to severe disease caused by influenza infection. 31, 32 Our findings that patients with CVID comprised a large proportion of our cohort (>30%), and that 4 of these patients died (45% of all deaths), may infer that intact humoral immunity is important for host defense against SARS-CoV-2. However, these patients were generally older than the rest of the cohort (median age range, 45-54 years), and many had pre-existing health conditions that predispose to severe COVID-19 in the general population (lung disease in ;50%, kidney/heart/gut/liver disease in ;20%; Table II) .

Second, with the exception of the patient with X-CGD with Burkholderia sepsis, the other 3 patients with CGD had relatively mild disease, suggesting a modest contribution of neutrophil function in anti-SARS-CoV-2 immunity.

Third, mild or asymptomatic disease in SARS-CoV-2 1 patients with dominant negative STAT3 variants, despite pre-existing chronic lung disease, suggests that STAT3 signaling contributes to the cytokine storm characteristic of severe COVID-19. Together with findings that serum IL-6 levels are greatly increased during SARS-CoV-2 infection, 6,33-35 and predict mortality in severe COVID-19, 36, 37 our data suggest that IL-6/ STAT3 contributes to the inflammatory response and subsequent disease severity in COVID-19. Based on this, mild disease in XLA may reflect not only B-cell deficiency but also impaired IL-6 production by BTK-deficient myeloid cells, 38 potentially ameliorating SARS-CoV-2-induced cytokine storm.

Fourth, all patients with autoinflammatory diseases were asymptomatic or stayed at home. However, most of these patients were young children, and both adults were treated with IL-1 blockade and colchicine.

Two recent studies provide convincing evidence that disruption of type I IFN signaling is a frequent cause of life-threatening COVID-19. 39, 40 In the first study, 650 patients with lifethreatening COVID-19 were studied by whole-exome sequencing under the hypothesis that severe COVID-19 is allelic with severe influenza 39 or that genes biologically related to these loci would be involved. 31, 32 Indeed, 3.5% of patients had known (AR IRF7 and IFNAR1 deficiency, autosomal-dominant TLR3, TICAM1, TBK1, and IRF3 deficiency) and new (autosomal-dominant UNC93B1, IRF7, IFNAR1, and IFNAR2 deficiency) genetic defects abolishing induction or amplification of type I IFNs. 39 In the second study, neutralizing autoantibodies against type I IFNs were found in 10.2% of 987 patients with life-threatening COVID-19 pneumonia, resulting in low or undetectable serum levels of IFN-a during acute disease; 94% of the patients with autoantibodies were male. The net result of both the anti-IFN autoantibodies and the loss-of-function variants in crucial type I IFN pathway genes is a profound defect in type I IFN immunity, underlying life-threatening COVID-19 pneumonia.

Intriguingly, we observed mild disease in patients with interferonopathies (AGS) treated with JAK inhibitors, suggesting sufficient residual type I IFN to protect from severe initial infection. It was striking that patients with NFKB1 or NFKB2 mutations required hospitalization, with both NFKB2-deficient individuals being admitted to ICU (Table II) . Because the canonical and alternate NFKB pathways are activated in plasmacytoid dendritic cells to produce large amounts of type 1 IFNs, 41 severe COVID-19 in patients with NFKB1 or NFKB2 loss-of-function variants may be explained by deficient type I IFN responses. Similarly, an absence of type 1 IFN-producing myeloid cells may underlie COVID-19 due to GATA2 haploinsufficiency (Table I) . 42 Because autoimmunity is a frequent manifestation of CVID, it can be hypothesized that the presence or absence of anti-type I IFN autoantibodies predisposed patients with CVID to either life-threatening or mild disease after SARS-CoV-2 infection. The finding of neutralizing anti-IFN autoantibodies in some individuals with severe COVID-19 40 may also explain why patients with agammaglobulinemia generally did not develop severe COVID-19, and predict that COVID-19 may occur in some AIRE-deficient patients because these patients produce autoantibodies against type 1 IFNs. 43 Moving forward, it will be important to not only study the functionality of immune cells from patients with IEI in the context of innate IFN signaling but also assess these patients for neutralizing anti-type 1 IFN antibodies.

Several caveats of our study need to be recognized. First, asymptomatic or mildly symptomatic SARS-CoV-2-infected patients with IEI are likely to be underdiagnosed, mainly due to regional testing priorities contributing to an ascertainment bias of such a retrospective study. Second, because we were guided by the most recent update of IEI, [16] [17] [18] it is unlikely that all patients with IEI who have been infected with SARS-CoV-2 were captured by our survey. Indeed, the field of IEI continues to grow rapidly, with more than 35 novel genetic defects having been described since the last update by the International Union of Immunological Societies committee. Thus, we have not considered SARS-CoV-2 infection in individuals with these putative novel monogenic causes of immune dysregulation. Third, if our survey accurately reflects the true incidence of COVID-19 in IEI, it suggests that immunodeficient patients have been less frequently infected and are less symptomatic than the general population. This could be explained by patients with IEI being informed early in the pandemic about safety measures by patient and scientific organizations. Moreover, patients with IEI are familiar with frequent sanitation practices, avoiding crowds, physical distancing, selfisolation, and so forth, as recommended during this pandemic. Fourth, our study does not include any patients with known defects of type I IFN pathways. On the basis of findings from studies of severe influenza, 31, 32 and recent investigation of the genetics of life-threatening SARS-CoV-2 infection, 39 these patients are even more strongly advised to practice strict hand hygiene, mask wearing, and social distancing than other patients with PID.

We report the course of COVID-19 in 94 patients with IEI. The survey revealed that a substantial subgroup of patients with IEI suffer only a mild course of disease. Risk factors predisposing to severe disease and mortality among patients with IEI were comparable to those in the general population. However, younger patients with IEI were more severely affected and more frequently admitted to ICU compared with the general population. These findings warrant recommendation for further stringent personal protective measures for patients affected by IEI. The urgent need to document the impact of SARS-CoV-2 on patients with defined IEIs is currently being met by registries developed by additional organizations (eg, ESID registry, ERN-RITA joint effort, and COPID19), as well as the COVID Human Genetic Effort, which is performing large-scale genetic and functional studies on patients affected by severe COVID-19. 15, 39, 40 Ideally, these studies will also include prospective longitudinal analysis to determine the long-term impact of SARS-CoV-2 even in convalescent individuals. These initiatives will further our insight into susceptibility of individual patients with IEI to disease. This will not only reveal necessary and redundant pathways for host defense against SARS-CoV-2 but also identify those that mediate collateral tissue damage in response to viral infection. Collectively, this and future studies have the potential to provide opportunities for immune modulation to treat COVID-19 in patients with IEI as well as the general population. Clinical implications: Risk factors predisposing to severe disease and mortality after SARS-CoV-2 infection in patients with IEI were similar to those in the general population. Notwithstanding inclusion and diagnostic bias, admission rates to ICU tended to be higher and median age of affected patients lower than in the general population.

World Health Organization. Coronavirus disease (COVID-19) pandemic

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

A novel coronavirus from patients with pneumonia in China

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Clinical and immunological features of severe and moderate coronavirus disease 2019

Should we stimulate or suppress immune responses in COVID-19? Cytokine and anticytokine interventions

Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship

Estimates of the severity of coronavirus disease 2019: a model-based analysis

Coronavirus disease 2019 case surveillance-United States

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study

Multisystem inflammatory syndrome in U.S. children and adolescents

COVID Human Genetic, Effort, A global effort to define the human genetics of protective immunity to SARS-CoV-2 infection

Human inborn errors of immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee

Human inborn errors of immunity: 2019 Update of the IUIS Phenotypical Classification

Human inborn errors of immunity: an expanding universe

A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia

Two Xlinked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover

A male infant with COVID-19 in the context of ARPC1B deficiency

Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma

COVID-19 presenting with autoimmune hemolytic anemia in the setting of underlying immune dysregulation

Three copies of four interferon receptor genes underlie a mild type I interferonopathy in Down syndrome

Inborn errors of adaptive immunity in Down syndrome

HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Implications of sex differences in immunity for SARS-CoV-2 pathogenesis and design of therapeutic interventions

Human genetics of life-threatening influenza pneumonitis

Recent human genetic errors of innate immunity leading to increased susceptibility to infection

The role of interleukin-6 in monitoring severe case of coronavirus disease 2019

Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Higher levels of IL-6 early after tocilizumab distinguish survivors from non-survivors in COVID-19 pneumonia: a possible indication for deeper targeting IL-6

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan

Bruton tyrosine kinase mediates TLR9-dependent human dendritic cell activation

Inborn errors of type I IFN immunity in patients with severe COVID-19

Autoantibodies against type I IFNs in patients with life-threatening COVID-19 [published online ahead of print

Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells

Lethal influenza in two related adults with inherited GATA2 deficiency

Antiinterferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1

We thank all the patients and clinicians involved in the care for these patients. We also thank the European Society for Immunodeficiencies, Clinical Immunology Society, Latin American Society for Immunodeficiencies, African Society for Immunodeficiencies, Asia Pacific Society for Immunodeficiencies, Australasian Society for Clinical Immunology & Allergy, the International Patient Organization for Primary Immunodeficiencies, and the Jeffrey Modell Foundation for distributing and promoting the e-survey to their members.Membership of the International Union of Immunological Societies Committee of Inborn Errors of Immunity: Waleed Al-Herz, Aziz Bousfiha, Charlotte Cunningham-Rundles, Jose Luis Franco, Steven M. Holland,